The French firm will use the proceeds to advance its ALIGATER platform for delivering genetic payloads and move its preclinical assets toward the clinic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback